Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension

Respiratory Medicine

Volumn 104, Issue 4, 2010, Pages 481-496

  Tonelli, Adriano R ^a   Alnuaimat, Hassan ^a   Mubarak, Kamal ^a  

^a Department of Internal Medicine   (United States)

Author keywords

Epoprostenol; Nitric oxide; Pulmonary artery drug effects; Pulmonary hypertension; Vascular resistance drug effects; Vasodilator agents diagnostic use

Indexed keywords

ADENOSINE; ANOREXIGENIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; ILOPROST; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; VASODILATOR AGENT;

HEART OUTPUT; HUMAN; IDIOPATHIC DISEASE; LUNG ARTERY PRESSURE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SURVIVAL; VASODILATATION; DIAGNOSTIC USE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HYPERTENSION, PULMONARY;

ADENOSINE; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; EPOPROSTENOL; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; NITRIC OXIDE; VASODILATION; VASODILATOR AGENTS;

EID: 77349113347     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.11.015     Document Type: Review

References (111)

1. Rubin L.J. American College of Chest Physicians. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 7S-10S
2. Simonneau G., Galiè N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 (2004) 5S-12S
3. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54 (2009) S43-S54
4. McGoon M., Gutterman D., Steen V., et al. American College of Chest Physicians. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 14S-34S
5. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., and McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 (2007) 1917-1928
6. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53 (2009) 1573-1619
7. Badesch D.B., Champion H.C., Sanchez M.A., et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54 (2009) S55-S66
8. Galiè N., Torbicki A., Barst R., et al. Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
9. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
10. Chin K.M., and Rubin L.J. Pulmonary arterial hypertension. J Am Coll Cardiol 51 (2008) 1527-1538
11. Weir E.K., Rubin L.J., Ayres S.M., et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 140 (1989) 1623-1630
12. Hoeper M.M., Lee S.H., Voswinckel R., et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48 (2006) 2546-2552
13. Oliveira E.C., Amaral C.F., Moura M.A., Campos F.T., and Pauperio H.M. Testing pulmonary vasoreactivity. J Bras Pneumol 34 (2008) 838-844
14. Groves B.M., Badesch D.B., Turkevich D., et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir K. (Ed). In flux in pulmonary vascular control (1993), Plenum Press, New York
15. Sitbon O., Humbert M., Jagot J.L., et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 12 (1998) 265-270
16. Badesch D.B., Abman S.H., Ahearn G.S., et al. American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 35S-62S
17. Rich S., Kaufmann E., and Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327 (1992) 76-81
18. Partanen J., Nieminen M.S., and Luomanmäki K. Death in a patient with primary pulmonary hypertension after 20 mg of nifedipine. N Engl J Med 329 (1993) 812
19. Barst R.J., Gibbs J.S., Ghofrani H.A., et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54 (2009) S78-S84
20. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 80 (1989) IV59-IV67
21. Hill N.S., and Klings E.S. General therapeutic approach and traditional therapies. In: Hill N.S., and Farber H.W. (Eds). Contemporary cardiology: pulmonary hypertension (2008), Humama Press, New Jersey
22. Sitbon O., Humbert M., Jaïs X., et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111 (2005) 3105-3111
23. Naeije R., and Vachiéry J.L. Medical therapy of pulmonary hypertension. Conventional therapies. Clin Chest Med 22 (2001) 517-527
24. Morales-Blanhir J., Santos S., de Jover L., et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 98 (2004) 225-234
25. Rubenfire M., Krishnan S., and Montgomery D. Reponse to inhaled nitric oxide (iNO) does not predict long term mortality in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 179 (2009) A2668
26. Raffy O., Azarian R., Brenot F., et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 93 (1996) 484-488
27. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 (1999) 1197-1208
28. Ricciardi M.J., Knight B.P., Martinez F.J., and Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 32 (1998) 1068-1073
29. Sitbon O., Brenot F., Denjean A., et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 151 (1995) 384-389
30. Rich S., and Brundage B.H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 76 (1987) 135-141
31. Rich S., D'Alonzo G.E., Dantzker D.R., and Levy P.S. Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. Am J Cardiol 55 (1985) 159-163
32. Rich S., Brundage B.H., and Levy P.S. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation 71 (1985) 1191-1196
33. Costa E.L., Jardim C., Bogossian H.B., Amato M.B., Carvalho C.R., and Souza R. Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria. Vascul Pharmacol 43 (2005) 143-147
34. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107 (1987) 216-223
35. Pietra G.G., Edwards W.D., Kay J.M., et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 80 (1989) 1198-1206
36. Bjornsson J., and Edwards W.D. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 60 (1985) 16-25
37. Wagenvoort C.A., and Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 42 (1970) 1163-1184
38. Rich S., and Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J Am Coll Cardiol 18 (1991) 1323-1327
39. Schrader B.J., Inbar S., Kaufmann L., Vestal R.E., and Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 19 (1992) 1060-1064
40. McLaughlin V.V., Genthner D.E., Panella M.M., and Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 (1998) 273-277
41. Thenappan T., Shah S.J., Rich S., and Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 30 (2007) 1103-1110
42. Jing Z.C., Jiang X., Han Z.Y., et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 33 (2009) 1354-1360
43. Galiè N., Ussia G., Passarelli P., Parlangeli R., Branzi A., and Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 75 (1995) 55A-62A
44. Ghofrani H.A., Wilkins M.W., and Rich S. Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation 118 (2008) 1195-1201
45. Zimmerman P., Brown L., Schmidt J., et al. Pulmonary arterial hypertension: is there a vasoreactive phenotype?. Am J Respir Crit Care Med 179 (2009) A2650
46. Widimský J., Morpurgo M., and Jezek V. Haemodynamic requirements for an ideal pulmonary vasodilator. Eur Heart J 9 Suppl. J (1988) 23-28
47. Yamaki S., and Wagenvoort C.A. Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients. Br Heart J 54 (1985) 428-434
48. Rosenzweig E.B., Morse J.H., Knowles J.A., et al. Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant 27 (2008) 668-674
49. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 20 (1958) 557-570
50. Hoeper M.M., Olschewski H., Ghofrani H.A., et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 35 (2000) 176-182
51. Packer M. Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards. Ann Intern Med 103 (1985) 258-270
52. Higenbottam T., Pepke-Zaba J., Scott J., et al. Inhaled "endothelial derived-relaxing factor" (EDRF) in primary hypertension (PPH). Am Rev Resp Dis 137 (1988) A107
53. Pepke-Zaba J., and Higenbottam T.W. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338 (1991) 1173-1174
54. IchNOse F., Roberts Jr. J.D., and Zapol W.M. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 109 (2004) 3106-3111
55. Atz A.M., Adatia I., Lock J.E., and Wessel D.L. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 33 (1999) 813-819
56. Jolliet P., Bulpa P., Thorens J.B., Ritz M., and Chevrolet J.C. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. Thorax 52 (1997) 369-372
57. Opitz C.F., Wensel R., Bettmann M., et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 24 (2003) 356-365
58. Frampton M.W., Morrow P.E., Cox C., Gibb F.R., Speers D.M., and Utell M.J. Effects of nitrogen dioxide exposure on pulmonary function and airway reactivity in normal humans. Am Rev Respir Dis 143 (1991) 522-527
59. Steudel W., Hurford W.E., and Zapol W.M. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 91 (1999) 1090-1121
60. Pearl J.M., Nelson D.P., Raake J.L., et al. Inhaled nitric oxide increases endothelin-1 levels: a potential cause of rebound pulmonary hypertension. Crit Care Med 30 (2002) 89-93
61. Aranda M., and Pearl R.G. Inhaled nitric oxide and pulmonary vasoreactivity. J Clin Monit Comput 16 (2000) 393-401
62. Gomberg-Maitland M., and Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 31 (2008) 891-901
63. Palevsky H.I., and Fishman A.P. Comparison of acute hemodynamic responses to prostacyclin with standard vasodilators in patients with primary pulmonary hypertension. Chest 93 (1988) 179S
64. Nootens M., Schrader B., Kaufmann E., Vestal R., Long W., and Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 107 (1995) 54-57
65. Humbert M., Sitbon O., and Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 351 (2004) 1425-1436
66. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
67. Olschewski H., Simonneau G., Galiè N., et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
68. Wilkens H., Guth A., König J., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104 (2001) 1218-1222
69. Pelleg A., and Porter R.S. The pharmacology of adenosine. Pharmacotherapy 10 (1990) 157-174
70. Reeves J.T., Groves B.M., and Weir E.K. Adenosine and selective reduction of pulmonary vascular resistance in primary pulmonary hypertension. Circulation 84 (1991) 1437-1439
71. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
72. Morgan J.M., McCormack D.G., Griffiths M.J., Morgan C.J., Barnes P.J., and Evans T.W. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 84 (1991) 1145-1149
73. Preston I.R., Klinger J.R., Houtches J., Nelson D., Farber H.W., and Hill N.S. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. Respir Med 99 (2005) 1501-1510
74. Stocker C., Penny D.J., Brizard C.P., Cochrane A.D., Soto R., and Shekerdemian L.S. Intravenous sildenafil and inhaled nitric oxide: a randomized trial in infants after cardiac surgery. Intensive Care Med 29 (2003) 1996-2003
75. Packer M. Is it ethical to administer vasodilator drugs to patients with primary pulmonary hypertension?. Chest 95 (1989) 1173-1175
76. Sitbon O., Humbert M., Jais X., et al. Acute vasodilator responsiveness and long-term response to calcium-channel blockers in different forms of pulmonary arterial hypertension. Am J Respir Crit Care Med 169 (2004) A210
77. Elliott C.G., Glissmeyer E.W., Havlena G.T., et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 113 (2006) 2509-2515
78. Newman J.H., Trembath R.C., Morse J.A., et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 43 (2004) 33S-39S
79. Sztrymf B., Coulet F., Girerd B., et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 177 (2008) 1377-1383
80. Simonneau G., Fartoukh M., Sitbon O., et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 114 (1998) 195S-199S
81. Klings E.S., Hill N.S., Ieong M.H., Simms R.W., Korn J.H., and Farber H.W. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 42 (1999) 2638-2645
82. Alpert M.A., Pressly T.A., Mukerji V., et al. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol 68 (1991) 1687-1691
83. ShNOhara S., Murata I., Yamada H., et al. Combined effects of diltiazem and oxygen in pulmonary hypertension of mixed connective tissue disease. J Rheumatol 21 (1994) 1763-1765
84. Sfikakis P.P., Kyriakidis M.K., Vergos C.G., et al. Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril. Am J Med 90 (1991) 541-546
85. Williamson D.J., Hayward C., Rogers P., et al. Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension. Circulation 94 (1996) 477-482
86. Strange C., Bolster M., Mazur J., Taylor M., Gossage J.R., and Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 118 (2000) 1077-1082
87. Jais X., Launay D., Yaici A., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum 58 (2008) 521-531
88. Farber H.W., Graven K.K., Kokolski G., and Korn J.H. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol 26 (1999) 1195-1196
89. Preston I.R., Klinger J.R., Houtchens J., Nelson D., Mehta S., and Hill N.S. Pulmonary edema caused by inhaled nitric oxide therapy in two patients with pulmonary hypertension associated with the CREST syndrome. Chest 121 (2002) 656-659
90. Aguilar R.V., and Farber H.W. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 162 (2000) 1846-1850
91. Petitpretz P., Brenot F., Azarian R., et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 89 (1994) 2722-2727
92. Opravil M., Pechère M., Speich R., et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 155 (1997) 990-995
93. Gildein H.P., Wildberg A., and Mocellin R. Comparative studies of hemodynamics under prostacyclin and nifedipine in patients with Eisenmenger syndrome. Z Kardiol 84 (1995) 55-63
94. Fix O.K., Bass N.M., De Marco T., and Merriman R.B. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 13 (2007) 875-885
95. Jones D.A., Benjamin C.W., and Linseman D.A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 48 (1995) 890-896
96. Degano B., Yaïci1 A., Le Pavec1 J., et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 33 (2009) 92-98
97. Galiè N., Beghetti M., Gatzoulis M.A., et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114 (2006) 48-54
98. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
99. Kuhlen R., Walbert E., Fränkel P., Thaden S., Behrendt W., and Rossaint R. Combination of inhaled nitric oxide and intravenous prostacyclin for successful treatment of severe pulmonary hypertension in a patient with acute respiratory distress syndrome. Intensive Care Med 25 (1999) 752-754
100. Aranda M., Bradford K.K., and Pearl R.G. Combined therapy with inhaled nitric oxide and intravenous vasodilators during acute and chronic experimental pulmonary hypertension. Anesth Analg 89 (1999) 152-158
101. Simonneau G., Rubin L.J., Galiè N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149 (2008) 521-530
102. Chan N.S., McLay J., and Kenmure A.C. Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide. Br Heart J 57 (1987) 207-209
103. Inbar S., Schrader B.J., Kaufmann E., Vestal R.E., and Rich S. Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. J Am Coll Cardiol 21 (1993) 413-418
104. McMurtry I.F., Davidson A.B., Reeves J.T., and Grover R.F. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res 38 (1976) 99-104
105. Kambara H., Fujimoto K., Wakabayashi A., and Kawai C. Primary pulmonary hypertension: beneficial therapy with diltiazem. Am Heart J 101 (1981) 230-231
106. Oudiz R.J., Casanova A., and Rubin L.J. Diagnostic work up of pulmonary arterial hypertension (PAH): data from the quality enhancement research initiative (QuERI). Am J Respir Crit Care Med 179 (2009) A2666
107. McLaughlin V., Langer A., Dragomir A., et al. Treatment of pulmonary arterial hypertension (PAH): data from the quality enhancement research initiative. Am J Respir Crit Care Med 179 (2009) A1043
108. Batra A.K., Segall P.H., and Ahmed T. Pulmonary edema with nifedipine in primary pulmonary hypertension. Respiration 47 (1985) 161-163
109. Packer M., Medina N., and Yushak M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol 4 (1984) 890-901
110. Aromatorio G.J., Uretsky B.F., and Reddy P.S. Hypotension and sinus arrest with nifedipine in pulmonary hypertension. Chest 87 (1985) 265-267
111. Farber H.W., Karlinsky J.B., and Faling L.J. Fatal outcome following nifedipine for pulmonary hypertension. Chest 83 (1983) 708-709